Therefore, most clinical trials of disease-modifying treatment (DMT) drugs focus on the primary targets of Aβ and tau protein for AD prevention or therapy, such as solanezumab [4], avagacestat [5], and idalopirdine [6]. The gene discussed is MAPT; the disease is Alzheimer disease.